ZTS

Zoetis Inc. Class A Common Stock (ZTS)

Stock · NYSE · Health Care

$77.34as of 8/28/2026

AI Market Commentary

AI-generated

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

August 30, 2026

Zoetis Gets Lowered Price Target as Analysts Reassess Animal Health Outlook. TD Cowen kept its positive stance on Zoetis but cut its price target from a higher level to $94, according to a Benzinga report. The move suggests the firm sees somewhat limited upside from current levels. Separately, Seeking Alpha featured Zoetis among healthcare dividend stocks highlighted for income-focused investors, noting its dividend yield and consistent payout history. The stock has traded within a wide 52-week range, and the revised target sits below the analyst average of $104.19.

Active signals

Support level
$74.48
Industry
Biotechnology: Pharmaceutical Preparations

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
14,500

Fundamentals

1-day range
$75.2$77.71
Market cap
$32.32B
P/E (trailing)
11.54
P/E (forward)
11.84
EPS (trailing)
$6.08
Dividend yield
1.64%
Beta
0.73
Avg. volume
6.52M
Ex-dividend date
July 20, 2026
Dividend pay date
September 1, 2026
52-week range
$71$156.49
Next earnings: November 3, 2026 · EPS estimate $1.51Before Openconfirmed

How Zoetis Inc. Class A Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$9.47BNet Income$2.67B (28%)Cost of Revenue$2.67B (28%)SG&A$2.38B (25%)Other$1.06B (11%)Tax$687.00M (7%)ZTS

Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub

Forecasts

15 analyst ratings

Buy 54%
Hold 46%
Sell 0%
1-year price forecast
High
$155
+100.4%
Median
$94
+21.5%
Low
$80
+3.4%

Zoetis Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

  • ZTS
    Zoetis Inc. Class A Common Stock
    $77.36
    ▲ 3.12%
    Market cap $32.32BP/E 11.54
    $71$156.49
  • ONC
    BeOne Medicines Ltd. American Depositary Shares
    $366.79
    ▼ 1.53%
    Market cap $34.88BP/E 88.12
    $205.51$346
  • ROIV
    Roivant Sciences Ltd. Common Shares
    $34.71
    ▼ 7.64%
    Market cap $24.08BP/E
    $11.85$37.97
  • UTHR
    United Therapeutics Corporation Common Stock
    $515.57
    ▼ 2.34%
    Market cap $21.92BP/E 17.03
    $302.19$609.35
  • INSM
    Insmed Incorporated Common Stock
    $118.52
    ▼ 2.36%
    Market cap $21.34BP/E
    $90.39$212.75
  • VTRS
    Viatris Inc. Common Stock
    $16.34
    ▼ 3.26%
    Market cap $20.53BP/E
    $9.43$18.39
  • JAZZ
    Jazz Pharmaceuticals plc Common Stock (Ireland)
    $244.6
    ▼ 2.59%
    Market cap $15.80BP/E 16.97
    $123.88$266.38

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions
Acquired
6.5K
Disposed
18.0K

Institutional Ownership

March 31, 2026

Total shares held
377.95M
Total value held
$43.21B
Institutional holders
1575
Top holders this quarter
  • Unknown35.58M
  • Unknown26.07M
  • Unknown19.32M
  • Unknown15.89M
  • Unknown14.15M
  • Unknown11.35M
  • Unknown10.15M
  • Unknown5.87M
  • Unknown5.66M
  • Unknown5.55M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.